ARTICLE | Deals
Neuro deal flow: pharmas pinning hopes on new modalities, delivery technologies
The last three years of deals prioritize new modalities against known targets and CNS entry over discovery of new targets
May 20, 2021 11:06 PM UTC
Though few pharmas have jumped back into neurology with two feet, steady deal-flow over the last three years suggests major players are actively testing the waters, mainly scouting for new modalities and CNS-penetrating technologies that could break down some of the barriers to success.
BioCentury analyzed 100 publicly disclosed in-licensing deals, research collaborations and asset purchases by 30 pharmas and big biotechs over the last three-plus years (2018-1Q21) and found at least 25 of the companies had announced a deal in the space...